FDA Asks If PRO Used For Shire's Firazyr Is Clinically Meaningful
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA finds no faults with self-administration for the hereditary angioedema drug as it takes the new molecular entity to a June 23 advisory panel.
You may also be interested in...
Shire Gets Advisory Committee Support For Firazyr Self-Administration Claim
Shire will enter discussions with FDA on labeling for its hereditary angioedema drug Firazyr (icatibant) with backing from an advisory panel for a claim to allow patients to self-administer the product, which is delivered through subcutaneous injection.
Shire Gets Advisory Committee Support For Firazyr Self-Administration Claim
Shire will enter discussions with FDA on labeling for its hereditary angioedema drug Firazyr (icatibant) with backing from an advisory panel for a claim to allow patients to self-administer the product, which is delivered through subcutaneous injection.
FDA’s Benlysta Approval: A Lesson In Overcoming Unvalidated Endpoints
A novel composite primary endpoint created by Human Genome Sciences with FDA’s blessing helped Benlysta (belimumab) obtain approval for lupus – one of contemporary drug development’s most challenging indications – despite the absence of a standard disease outcome measure.